PMOS Reclassification Could Open the Door to GLP-1 Coverage for Millions of Women

A shift in medical terminology may change how women access treatment for a common hormonal disorder. The condition once called Polycystic Ovarian Syndrome, or PCOS, now has a new name: Polyendocrine Metabolic Ovarian Syndrome, or PMOS. Moreover, the change followed more than a decade of research and advocacy. Over 14,000 patients and clinicians contributed input through the Endocrine Society.

For roughly 1 in 8 women affected globally, the implications go well beyond a name. PMOS is the leading cause of infertility. Symptoms include irregular periods, weight gain, and excessive hair growth. Many women also experience significant mental health challenges as a result.

Diagnosis is notoriously difficult. On average, it takes at least a year and three or more clinical visits. Furthermore, some women spend years cycling through misdiagnoses before getting answers.

The core problem, according to Dr. Melanie Cree, is metabolic. Cree is a physician and researcher at the University of Colorado Anschutz and a central figure in the renaming effort. Women with PMOS tend to have elevated insulin levels. That excess insulin, in turn, signals the ovaries to overproduce testosterone. Consequently, that hormonal imbalance drives most of the syndrome’s symptoms.

Excess weight worsens insulin resistance. Likewise, insulin resistance makes weight loss harder. The cycle is thus self-reinforcing.

That is where GLP-1 receptor agonists enter the picture. Drugs like semaglutide are marketed by Novo Nordisk as Ozempic and Wegovy. They reduce circulating insulin through a glucose-dependent mechanism. As a result, lower insulin levels appear to quiet excess testosterone production in the ovaries.

Cree’s findings are notable. Women using semaglutide who lost 10% or more of their body weight saw testosterone fall by an average of 51%. Indeed, six of eight women in the study also showed improved menstrual regularity by trial’s end. These results will appear in a forthcoming paper in Fertility and Sterility.

Nevertheless, formal FDA approval of GLP-1 drugs specifically for PMOS is not expected soon. The condition’s symptom variability makes clinical trials difficult to design. There is also a serious safety concern. Restoring hormonal balance can trigger ovulation resumption. Consequently, that raises a meaningful risk of unintended pregnancy during trials.

Cree has noted that this liability makes such studies hard to pursue. Accordingly, her lab requires participants to avoid pregnancy throughout enrollment. Novo Nordisk confirmed no immediate plans to seek a PMOS indication. Eli Lilly did not respond to a request for comment.

In the near term, however, the name change may help women access GLP-1 coverage through an existing route. These medications already carry FDA approval for type 2 diabetes, obesity, severe metabolic liver disease, and obstructive sleep apnea. Notably, women with PMOS develop all of these at higher rates.

The CDC estimates more than half will develop type 2 diabetes by age 40. Furthermore, they are up to four times more likely to develop Metabolically Dysregulated-Associated Steatotic Liver Disease. One study also found they are 30 times more likely to have obstructive sleep apnea, even after controlling for body weight.

The old name, PCOS, narrowed clinical focus. It implied ovarian cysts were central to the diagnosis. In reality, many affected women have excess follicles, not true cysts. Hence, clinicians often missed the broader metabolic picture entirely.

The new name, PMOS, places metabolic dysfunction and endocrine dysfunction at the center of the diagnosis. That framing, therefore, supports more comprehensive metabolic screening. Those screenings may, in turn, uncover co-occurring conditions already eligible for GLP-1 coverage.

Cree’s advice for patients is direct: request a full metabolic workup. A confirmed co-occurring condition, such as type 2 diabetes, liver disease, or sleep apnea, may accordingly unlock insurance coverage for GLP-1 therapy. That pathway will not work for every patient. For many women who have gone years without effective treatment, however, it may be the most immediate option available.